ENOV vs INVA vs HOLX vs PRGO vs TEVA

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Enovis Corporation (ENOV) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Hologic, Inc. at 30. 5x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +248.

6%, compared to -63. 9% for Enovis Corporation (ENOV). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 11β versus Enovis Corporation's 2. 04β — meaning ENOV is approximately 1695% more volatile than INVA relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ENOV leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -52. 7% for Enovis Corporation — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -52. 6% for ENOV. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 17. 2x for Hologic, Inc. — 11. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

In this comparison, PRGO (9.

8% yield) pays a dividend. ENOV, INVA, HOLX, TEVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 11)). Enovis Corporation (ENOV) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +95. 6%, ENOV: -39. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ENOV (Industrials) and INVA (Healthcare) and HOLX (Healthcare) and PRGO (Healthcare) and TEVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ENOV is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; HOLX is a mid-cap quality compounder stock; PRGO is a small-cap income-oriented stock; TEVA is a mid-cap quality compounder stock. PRGO pays a dividend while ENOV, INVA, HOLX, TEVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.